biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by Sniper007on Apr 11, 2013 4:56pm

200 Views

Post# 21243904

Anti-TNF market alone in excess of 30 Billion?

Pmrider had mentioned in his latest post that the potential market for BTI was in excess of 30 billion. I found the following on Wikipedia and thought I would share it. It's missing the 2010-2011 data but a chart would seem to indicate that the anti-TNF market alone could well have been in excess of 30 billion for 2010 and 2011.

WIKIPEDIA - TNF INHIBITOR: The global market for TNF inhibitors in 2007 was $10Bn,^{[citation needed]} and in 2008 it was $13.5Bn^[2] and $22Bn in 2009.^[3]

^{Not sure of the accuracy but it could well be correct.}

^Sniper

Bullboard Posts

Unique Battery Metals opportunity in Quebec